Literature DB >> 17103065

Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.

Brian Hung-Hin Lang1, Chung-Yau Lo, Wai-Fan Chan, King-Yin Lam, Koon-Yat Wan.   

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are two distinct histological types of thyroid carcinoma but have often been studied and staged as a collective group, known as differentiated thyroid carcinoma (DTC). However, this may not be an optimal approach to cancer staging.
METHODS: A total of 760 patients with DTC, comprising 589 (77.5%) with PTC and 171 with (22.5%) FTC, being managed at our institution from 1961 to 2001 were retrospectively reviewed. Their clinicopathological features, treatment modalities received, and postoperative outcome were analyzed. Both univariate and multivariate analyses were performed to identify prognostic factors related to cancer-specific survival (CSS) for PTC and FTC.
RESULTS: There were statistically significant differences between PTC and FTC in terms of age >/=50 years at diagnosis (P = .040), tumor size (P < .001), lymph node metastases (P < .001), distant metastases (P < .001), extrathyroidal extension (P < .001), multifocality (P = .002), capsular invasion (P < .001), extent of thyroid resection (P < .001), radioiodine ablation (P < .001), and external-beam irradiation (P = .003). Although PTC and FTC had similar 10-year and 15-year CSS (P = .846), each possessed its own set of independent prognostic factors for CSS. Age at diagnosis and completeness of resection were independent prognostic factors in both PTC and FTC.
CONCLUSIONS: There were marked differences in clinicopathologic features, treatment, and prognostic factors between the two histologic types of DTC. Different staging systems should be evaluated and validated for PTC and FTC individually in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103065     DOI: 10.1245/s10434-006-9207-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

1.  [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].

Authors:  M Stratmann; C Sekulla; H Dralle; M Brauckhoff
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

2.  Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions.

Authors:  Eduardo Anselmo Garcia; Kleber Simões; Alda Wakamatsu; Rodrigo Albergaria Ressio; Venâncio Avancini Ferreira Alves; Adhemar Longatto-Filho; Roberto Souza Camargo
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

4.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

5.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

Review 6.  Management of Invasive Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Ricard Simo; Kate Newbold; Alessandra Rinaldo; Carlos Suarez; Luiz P Kowalski; Carl Silver; Jatin P Shah; Alfio Ferlito
Journal:  Thyroid       Date:  2016-08-23       Impact factor: 6.568

7.  Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction.

Authors:  Dom-Gene Tu; Wen-Wei Chang; Ming-Shiou Jan; Chi-Wen Tu; Yin-Che Lu; Chien-Kuo Tai
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

8.  Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology.

Authors:  Paul A VanderLaan; Ellen Marqusee; Jeffrey F Krane
Journal:  Cancer Cytopathol       Date:  2012-03-20       Impact factor: 5.284

9.  EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer.

Authors:  Jing-Jing Li; Zhi-Jian Sun; Yan-Mei Yuan; Fen-Fen Yin; Yao-Gang Bian; Ling-Yun Long; Xue-Li Zhang; Dong Xie
Journal:  J Biol Chem       Date:  2016-12-16       Impact factor: 5.157

10.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.